Feature

Five-year survival for non-Hodgkin lymphoma tops 71%


 

The overall 5-year survival rate for non-Hodgkin lymphoma (NHL) is 71.4%, according to the National Cancer Institute.

That number falls neatly into the middle of the range for survival by stage at diagnosis, with stage I (81.8%) and stage II (75.3%) disease on the high side and stage III (69.1%) and stage IV (61.7%) on the low side, the most recent data from the Surveillance, Epidemiology, and End Results (SEER) Program show. Five-year survival for NHL of unknown stage at diagnosis is 76.4%.

Non-Hodgkin lymphoma: 5-year survival by stage at diagnosis
The SEER data from 2008-2014 also show that the largest proportion of NHL cases at diagnosis is stage IV (34%), followed by stage I (25%), stage III (16%), stage II (14%), and unstaged (11%), the NCI said.

Recommended Reading

Pregnancy did not increase Hodgkin lymphoma relapse rate
MDedge Internal Medicine
HIV-related lymphoma rate remains sky-high despite ART
MDedge Internal Medicine
Cancer trends shifting in HIV-positive patients
MDedge Internal Medicine
Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
MDedge Internal Medicine
Hodgkin lymphoma survival has nearly tripled since the 1950s
MDedge Internal Medicine
Long view shows doubling of survival in non-Hodgkin lymphoma
MDedge Internal Medicine
Neuropathic pain puts cancer survivors out of work
MDedge Internal Medicine
Phase III trial: VZV protects auto-HCT patients
MDedge Internal Medicine
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
MDedge Internal Medicine
Decline in non-Hodgkin lymphoma deaths to continue in 2018
MDedge Internal Medicine